Open access
Aug 2026
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.
It is reported that treatment of NSCLC KRAS G12C cells with sotorasib induces M1C expression by a STAT1-dependent pathway, and M1C drives the sotorasib resistant phenotype by NF-κB-mediated induction of the epithelial-mesenchymal transition and a mucinous gene program.
Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya et al.
· Oncogene · 1 citation